599 related articles for article (PubMed ID: 30172115)
1. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
Furue K; Ito T; Furue M
Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis and the TNF/IL23/IL17 axis.
Furue K; Ito T; Tsuji G; Kadono T; Furue M
G Ital Dermatol Venereol; 2019 Aug; 154(4):418-424. PubMed ID: 30648836
[TBL] [Abstract][Full Text] [Related]
3. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.
Boutet MA; Nerviani A; Gallo Afflitto G; Pitzalis C
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29425183
[TBL] [Abstract][Full Text] [Related]
4. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.
Sakkas LI; Bogdanos DP
Autoimmun Rev; 2017 Jan; 16(1):10-15. PubMed ID: 27666819
[TBL] [Abstract][Full Text] [Related]
5. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Blauvelt A; Chiricozzi A
Clin Rev Allergy Immunol; 2018 Dec; 55(3):379-390. PubMed ID: 30109481
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.
Kubin ME; Kokkonen N; Palatsi R; Hägg PM; Väyrynen JP; Glumoff V; Haapasaari KM; Hurskainen T; Tasanen K
Acta Derm Venereol; 2017 Apr; 97(4):449-455. PubMed ID: 27868150
[TBL] [Abstract][Full Text] [Related]
7. Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis.
Furue K; Yamamura K; Tsuji G; Mitoma C; Uchi H; Nakahara T; Kido-Nakahara M; Kadono T; Furue M
Acta Derm Venereol; 2018 Jan; 98(1):5-13. PubMed ID: 28967976
[TBL] [Abstract][Full Text] [Related]
8. The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis.
Vecellio M; Hake VX; Davidson C; Carena MC; Wordsworth BP; Selmi C
Front Immunol; 2020; 11():596086. PubMed ID: 33574815
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
[TBL] [Abstract][Full Text] [Related]
10. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
11. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
12. IL-17A and TNF-α-induced Dectin-1 expression may promote keratinocyte proliferation in psoriatic lesions.
Cui W; Liu J; Kong S; Huang H; Liu L; Cao Y; Gu Z
Eur J Dermatol; 2024 Apr; 34(2):119-130. PubMed ID: 38907541
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.
Tan WS; Kelly S; Pitzalis C
Expert Rev Clin Immunol; 2017 Mar; 13(3):207-222. PubMed ID: 27690678
[TBL] [Abstract][Full Text] [Related]
14. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
Victor FC; Gottlieb AB; Menter A
Clin Dermatol; 2003; 21(5):392-7. PubMed ID: 14678719
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
[TBL] [Abstract][Full Text] [Related]
19. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
[TBL] [Abstract][Full Text] [Related]
20. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis.
Witte E; Kokolakis G; Witte K; Philipp S; Doecke WD; Babel N; Wittig BM; Warszawska K; Kurek A; Erdmann-Keding M; Kunz S; Asadullah K; Kadin ME; Volk HD; Sterry W; Wolk K; Sabat R
J Invest Dermatol; 2014 Nov; 134(11):2757-2767. PubMed ID: 25046339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
